From the ann:
"Significant opportunity for Prima to tap into US$517 million Middle East cancer therapy market."
If Cvac were to capture only 1% of that entire market US$5 mill p.a. in immediate revenue.
Another way to look at it, Provenge is sold in the US for about $95,000 per patient.
Assume DHCC treats a mere 50 patients with Cvac per annum on the same cost basis, thats near enough US$5 mill again.
Apply a very conservative (for Biomeds)P/E of 16 times earnings and divide by (roughly) 1 bill shares on issue.
On those very conservative estimates, Dubai alone adds 8 cents per share in value.
so what is dubai worth?
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $569.8M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 39.0¢ | $1.746M | 4.422M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7395 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 94636 | 3 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |